Deep-sea technology captures images of WWI submarine, 100 years after it sank near San Diego
The USS F-1 was involved in a training accident eight days before Christmas Day in 1917, which killed all 19 crew members on board.
Three La Jolla homes designated 'historic' by San Diego board
With the help of advanced deep-sea imaging technology, researchers were able to capture high-quality images of the submarine's wreckage, discovered more than 1,300 feet under the ocean's surface just west of San Diego.
Researchers from the Woods Hole Oceanographic Institution (WHOI) dispatched a human-operated submersible called Alvin and another underwater vehicle called Sentry, both belonging to the National Deep Submergence Facility (NDSF), to capture the images. (See images below)
'While these depths were well within the dive capability for Alvin and Sentry, they were technical dives requiring specialized expertise and equipment,' said Anna Michel, co-lead of the expedition and NDSF chief scientist.
The team conducted surveys of the submarine using sonar systems on Sentry and a research vessel, Atlantis. They also surveyed the wreckage of a Navy Avenger torpedo bomber that crashed near the area where the USS F-1 sank.
'We were careful and methodical in surveying these historical sites so that we could share these stunning images, while also maintaining the reverence these sites deserve,' Michel stated.
A remembrance ceremony later took place onboard Atlantis to commemorate the lives lost during the submersible's training accident 100 years ago. A bell was rung 19 times in honor of each crew member lost at sea, according to a news release by the institution.
'As a Navy veteran, making this dive—together with another Navy veteran and a Navy historian—was a solemn privilege,' said ONR Program Officer Rob Sparrock, who was among those on board the Alvin. 'Lasting nearly eight hours, there was time to contemplate the risks that all mariners, past and present, face.'
The surveys and high-definition images of the USS F-1 were gathered with the assistance of the Office of Naval Research, the University-National Oceanographic Laboratory System, Naval History and Heritage Command and WHOI.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Geographic
7 hours ago
- National Geographic
Diet soda might be making you hungrier
The idea that diet sodas can help you lose weight is becoming increasingly complicated as emerging research suggests they may confuse the brain—and trigger an urge to eat. Artificial sweeteners in diet sodas can potentially trigger brain activity linked to hunger, raising questions about their role in weight control. Photograph By Narong KHUEANKAEW/ Istock/Getty Images Millions of people reach for diet sodas each day to reduce sugar intake, manage their weight, or make healthier choices. But new research suggests these artificially sweetened drinks may do more than satisfy a sweet tooth—they may also be quietly rewiring how the brain regulates hunger. Artificial sweeteners have long been controversial for their possible link to cancer and poor gut health. Yet some studies suggest that sweeteners like sucralose may stimulate the regions of the brain involved in hunger signaling, potentially triggering the urge to eat. Whether that leads to actual weight gain is less clear, but the idea that diet sodas support weight loss is becoming increasingly complicated. What does sucralose do differently than sugar When you eat or drink something with calories—such as a sugary soda—your body initiates a cascade of responses designed to manage energy. Glucose is absorbed into the bloodstream, your gut releases hormones like GLP-1 and leptin, and your pancreas produces insulin. Together, these signals tell the hypothalamus—the brain's hunger-regulating command center—that energy has arrived, helping you feel full and satisfied. (The surprising reason we can't stop thinking about junk food.) But that feedback loop breaks down when artificial sweeteners like sucralose enter the picture. Such changes can be observed through functional MRI scans showing activity in the hypothalamus and its connections to other brain regions, says Kathleen Page, an endocrinologist and director of the Diabetes and Obesity Institute at the University of Southern California's Keck School of Medicine. 'We think [the activity] may be a biomarker of satiety signaling,' she says. Eating glucose typically causes a decrease in hypothalamic activity, which is associated with feelings of fullness. Sucralose, an artificial sweetener, seems to increase the activity in the brain region instead. Page's team tested this by giving 75 young adults beverages sweetened with either sucralose, sucrose (table sugar), or plain water. They found that sucralose-sweetened beverages increased blood flow to the hypothalamus and resulted in increased hunger, while sucrose-sweetened beverages reduced blood flow and hunger. And unlike sucrose, they found that artificial sweeteners didn't increase levels of insulin and GLP-1 in the blood—some of the hormones linked to promoting satiety. Previous studies on mice show similar results. One possible explanation? A disconnect between taste and nutrition. Sucralose is hundreds of times sweeter than sugar but contains no calories. 'When the brain gets a signal of sweetness, it's anticipating that nutrients will follow,' Page says. But when they don't, the mismatch might stimulate appetite 'because the brain is still looking for that nutrient,' Page says, adding that this phenomenon has been observed in mice, which crave more sugary foods after they've consumed an artificial sweetener. Naturally flavored sparkling waters offer a no-sugar, no-sweetener option that some experts recommend over diet sodas for curbing cravings. Photograph By Olga Yastremska/ Alamy Artificial sweeteners don't just affect the brain; they affect metabolism too. A 2020 study found that when sucralose was consumed alongside carbohydrates—which are broken down into glucose in the body—it impaired glucose metabolism by making participants less sensitive to insulin. 'By adding an artificial sweetener, you change the metabolic fate of the glucose,' says Dana Small, a neuroscientist and psychologist specializing in metabolism at McGill University in Montreal and lead researcher of the study. Although artificial sweeteners appear to disrupt these signals, the evidence on whether that leads to weight gain is mixed. Several large cohort studies have linked artificial sweeteners with an increased risk of obesity and weight gain. One recent study found those who drank diet beverages daily were more likely to develop type 2 diabetes. Other new results show that high consumption of diet beverages and saccharin (but not aspartame or sucralose) is linked to a greater risk of developing diabetes. Another 20-year study found people accumulated more body fat if they were more frequent consumers of sweeteners. (Low-calorie sweeteners might not be as good for us as we thought.) But correlation isn't causation. 'People who drink artificial sweeteners are more likely to be thinking about their weight,' Small says. 'Is the artificial sweetener causing the weight gain, or is it the weight gain causing the artificial sweetener use?' Still, international agencies have incorporated these results into their health recommendations. The World Health Organization cautioned against using artificial sweeteners for weight management in 2023, citing evidence that linked them to increased risk of obesity and type 2 diabetes. Randomized controlled trials have also produced conflicting results. Some show that replacing sugary drinks with artificial sweeteners, especially as part of a weight loss program, can lead to a modest amount of weight loss. But other evidence shows the opposite. Results presented at this year's American Diabetes Association meeting showed women with type 2 diabetes who swapped diet drinks with water were twice as likely to go into remission. They also lost about 4.5 pounds more than those who continued drinking the diet beverages. The role of hunger—and why it might not matter Even as studies show that artificial sweeteners may stimulate appetite, some researchers argue that hunger itself may not be the main reason we eat. 'It's not so common that we actually eat because we're hungry and stop eating because we're full,' says Richard D. Mattes, a nutrition scientist at Purdue University in Indiana. Boredom, craving a sensory experience, or being in a social setting are among the other reasons people might start eating. 'Hunger is a relatively minor contributor to that,' he says. (Addicted to diet soda? Here's the history of its low-calorie secret weapon.) Ideally, everyone would drink plain water. 'But the issue is, people choose to use a beverage to satisfy other desires for sensory stimulation,' Mattes says. If a low-calorie sweetened beverage replaces an energy-rich beverage and helps people comply with a diet, then it serves a function, he added. Still, others urge more caution given the mounting evidence on the adverse health effects of the beverages. Page counsels her patients with diabetes against both sugary drinks and artificially sweetened ones, given how sweet taste, regardless of the source, may increase appetite or trigger cravings. For those who can't give up the fizz of soda, she recommends naturally flavored carbonated waters instead. 'The bottom line is that artificial sweeteners are not inert like they were once thought to be,' Small says. 'And I think the bulk of the evidence suggests that they're not healthy.'
Business Insider
15 hours ago
- Business Insider
AstraZeneca announces $50B of investment in U.S. by 2030
AstraZeneca (AZN) announces $50B of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar U.S. manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5B announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. 'The $50B investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland; State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts; Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; Continuous manufacturing expansion in Mount Vernon, Indiana; Specialty manufacturing expansion in Coppell, Texas; New sites to supply clinical trials. Our growing research and development investment in novel medicines. Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80B in Total Revenue by 2030, of which we expect 50% would be generated in the U.S.' Elevate Your Investing Strategy:
Business Wire
21 hours ago
- Business Wire
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.' Governor Glenn Youngkin, Commonwealth of Virginia, said: 'I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.' Pascal Soriot, Chief Executive Officer, AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines.' Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca.
